01—Abstract
Summary
Summary of the 8-K filed February 9, 2026. Cited figures are marked; the original filing is the authoritative source.
Labcorp Holdings Inc. (NYSE: LH) filed a Form 8-K on February 9, 2026, to report the appointment of John H.
Sampson, M.D., Ph.D., to its Board of Directors, effective February 9, 2026. The Board appointed Dr. Sampson on February 6, 2026, and assigned him to the Quality and Compliance Committee. He will receive compensation for Board service under the company's director compensation program, as described in its most recent proxy statement filed April 4, 2025.
Dr. Sampson is vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine. Previously he held senior leadership roles at Duke University Health System, where he served as senior vice president and led the Duke Health Integrated Practice. He is a practicing neurosurgeon, a member of the National Academy of Medicine, and has authored nearly 300 peer-reviewed publications.
The company says his expertise in oncology, neuroscience, women's health and personalized medicine aligns with its strategic focus areas. The filing is a governance announcement and does not disclose financial results, guidance, or transaction terms. The company issued a press release on February 9, 2026, announcing the appointment, which is filed as Exhibit 99.1.
02—Key points
Key Highlights
- Board appointment: John H. Sampson, M.D., Ph.D., joined the Board effective February 9, 2026, after being appointed on February 6, 2026.
- Committee assignment: Dr. Sampson was named to the Quality and Compliance Committee.
- Director compensation: He will be paid under the company's director compensation program described in the April 4, 2025 proxy statement.
- Clinical and academic background: He is vice chancellor and dean of the University of Colorado Anschutz School of Medicine and a practicing neurosurgeon.
- Prior leadership: He previously served as senior vice president at Duke University Health System and led the Duke Health Integrated Practice.
- Research profile: He is a member of the National Academy of Medicine and has authored nearly 300 peer-reviewed publications.
- Disclosure: The appointment was announced via a press release dated February 9, 2026 (Exhibit 99.1).
03—Questions
Frequently Asked Questions
Who is the new board member?
John H. Sampson, M.D., Ph.D., is vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine. He is also a practicing neurosurgeon and a member of the National Academy of Medicine.
When did the appointment take effect?
The Board appointed Dr. Sampson on February 6, 2026, and his appointment became effective February 9, 2026.
What committee will Dr. Sampson serve on?
The Board appointed him to the Quality and Compliance Committee.
How will Dr. Sampson be compensated?
He will receive compensation for Board service consistent with the company's director compensation program, as described in the proxy statement filed April 4, 2025.
Does the filing disclose any financial impact?
No. The filing is a governance announcement and does not report financial results, guidance, or transaction terms.
04—Continue